Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 5/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664560 | 0.86 | KDM4E (0.59) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL26607699 | 0.86 | KDM4E (0.53) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL16896940 | 0.86 | GRIN2D (0.57) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL12047270 | 0.86 | NQO2 (0.54) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL8700898 | 0.86 | NQO2 (0.54) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL5473245 | 0.86 | NQO2 (0.54) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL12047200 | 0.82 | CTSV (0.68) | NQO2KDM4EALDH1A1HPGDTNKS2 | |
| SCHEMBL30081022 | 0.81 | KDM4E (0.54) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL28314220 | 0.81 | KDM4E (0.54) | NQO2CYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL31365388 | 0.81 | KDM4E (0.50) | NQO2CYP19A1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731960-B2 | Biheterocyclic compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20220380353-A1 | BIHETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-01 | — | — | US | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-20210198242-A1 | BIHETEROCYCLIC COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| US-10870642-B2 | Biheterocyclic compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20190308958-A1 | BIHETEROCYCLIC COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-10-10 | — | — | US | disclosed |
| US-10323024-B2 | Biheterocyclic compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20190016711-A1 | BIHETEROCYCLIC COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-17 | — | — | US | disclosed |
| WO-2017122722-A1 | BIHETEROCYCLIC COMPOUND | 大日本住友製薬株式会社 | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380353-A1 | BIHETEROCYCLIC COMPOUND | NPY4R, NR4A3, OGFR | NQO2 2073/4885CYP19A1 434/4885KDM4E 883/4885 |
| US-11731960-B2 | Biheterocyclic compound | NR4A3, NGF, OGFR | NQO2 2217/4885CYP19A1 450/4885KDM4E 1008/4885 |
| US-20210198242-A1 | BIHETEROCYCLIC COMPOUND | NR4A3, NGF, OGFR | NQO2 2217/4885CYP19A1 450/4885KDM4E 1008/4885 |
| US-20190308958-A1 | BIHETEROCYCLIC COMPOUND | NR4A3, NGF, OGFR | NQO2 2217/4885CYP19A1 450/4885KDM4E 1008/4885 |
| US-10323024-B2 | Biheterocyclic compound | NR4A3, NGF, OGFR | NQO2 2217/4885CYP19A1 450/4885KDM4E 1008/4885 |
| US-10870642-B2 | Biheterocyclic compound | NR4A3, NGF, OGFR | NQO2 2217/4885CYP19A1 450/4885KDM4E 1008/4885 |
| US-20190016711-A1 | BIHETEROCYCLIC COMPOUND | NR4A3, NGF, OGFR | NQO2 2217/4885CYP19A1 450/4885KDM4E 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.